Prognostic Value of Urokinase Plasminogen Activator in Breast Cancer
Author Information
Author(s): C Bouchet, F Spyratos, K Hacene, L Durcos, V Becette, J Oglobine
Primary Institution: Centre Rene Huguenin, France
Hypothesis
The study aims to assess the prognostic value of two different immunoassay methods for measuring urokinase plasminogen activator (uPA) in breast cancer patients.
Conclusion
Both uPA measurement methods are strong independent prognostic factors for breast cancer outcomes.
Supporting Evidence
- High levels of uPA were associated with poor prognosis in breast cancer.
- Both uPA measurement methods provided significant prognostic information.
- Patients with high uPA levels had shorter overall survival and disease-free survival.
Takeaway
This study looked at a protein called uPA in breast cancer to see if it can help predict how well patients will do. They found that two different testing methods for uPA can give important information about patient outcomes.
Methodology
The study used two enzyme-linked immunosorbent assay (ELISA) methods to measure uPA levels in breast cancer cytosols from 499 patients.
Potential Biases
Potential bias due to differences in assay methods and their specificities.
Limitations
The two uPA measurement methods are not interchangeable despite a good correlation.
Participant Demographics
Median age of participants was 58 years, with a range from 24 to 84 years.
Statistical Information
P-Value
<0.0001
Confidence Interval
95% CI for relative risks provided in the study.
Statistical Significance
p<0.0001
Want to read the original?
Access the complete publication on the publisher's website